Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
IGKV1-37 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGKV1-37 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV1-37 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGKV1-27 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGKV1-27 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV1-27 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGKV1-39 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGKV1-39 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV1-39 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGKV1-17 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGKV1-17 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV1-17 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGKV1-16 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGKV1-16 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV1-16 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGKV1-12 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGKV1-12 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV1-12 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGHV8-51-1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGHV8-51-1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGHV8-51-1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGKV1-13 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGKV1-13 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV1-13 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGKC Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGKC Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKC sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGHV7-4-1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGHV7-4-1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGHV7-4-1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGHV5-10-1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGHV5-10-1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGHV5-10-1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGHV6-1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGHV6-1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGHV6-1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →